Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
4 pending office actions • 2 art units • 3 examiners • 0 of 4 (0%) have an AI response strategy ready
Octapharma AG currently has 4 pending office actions within the Biotechnology & Pharmaceuticals technology area. These 4 pending office actions are distributed among 3 distinct examiners. The prosecution activity is spread across 2 distinct art units. HOLLAND, PAUL J is the busiest examiner, managing 2 pending office actions. This concentration suggests that half of the company's current pending matters are under the review of a single examiner within the biotech sector.
The presence of 4 pending office actions in the Biotechnology & Pharmaceuticals sector indicates an active prosecution phase. While 3 distinct examiners are involved, the 2 distinct art units suggest some technical overlap in the filings. HOLLAND, PAUL J handles 2 pending office actions, making his specific examination style a key factor for the company. Practitioners should coordinate responses across the 2 distinct art units to ensure consistency for all 4 pending office actions and improve the likelihood of allowance.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §112 only | 2 (50%) |
| Double-patenting + other | 1 (25%) |
| Multi-statute (no §101) | 1 (25%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| HOLLAND, PAUL J | 2 | 57.5% | +64.6% |
| ROBINSON, HOPE A | 1 | 67.7% | +43.1% |
| KAMM, JUDITH MARIE | 1 | 43.5% | +56.6% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18812083 | C1-ESTERASE INHIBITOR PREPARATION | ROBINSON, HOPE A | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 4 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18812083 | C1-ESTERASE INHIBITOR PREPARATION | ROBINSON, HOPE A | — |
| 18837556 | BIODEGRADABLE, NON-POROUS MEDICAL DEVICE AND METHODS FOR MAKING AND USING THE SAME | KAMM, JUDITH MARIE | — |
| 18329503 | MEANS AND METHODS FOR MODIFYING MULTIPLE ALLELES | HOLLAND, PAUL J | — |
| 18329520 | MEANS AND METHODS FOR MODIFYING MULTIPLE ALLELES | HOLLAND, PAUL J | — |
| Art Unit | Apps |
|---|---|
| 1656 | 2 |
| 1611 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18812083 | C1-ESTERASE INHIBITOR PREPARATION | ROBINSON, HOPE A | — | §103§112 | Non-Final OA | — | Pending | Aug 22, 2024 |
| 18837556 | BIODEGRADABLE, NON-POROUS MEDICAL DEVICE AND METHODS FOR MAKING AND USING THE SAME | KAMM, JUDITH MARIE | 1611 | §102§103DPOther | Non-Final OA | — | Pending | Aug 09, 2024 |
| 18329503 | MEANS AND METHODS FOR MODIFYING MULTIPLE ALLELES | HOLLAND, PAUL J | 1656 | §112 | Non-Final OA | — | Pending | Jun 05, 2023 |
| 18329520 | MEANS AND METHODS FOR MODIFYING MULTIPLE ALLELES | HOLLAND, PAUL J | 1656 | §112 | Non-Final OA | — | Pending | Jun 05, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial